UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

A molecule isolated from sea sponges and synthesized at Harvard can halt the growth of cancerous cells.